| 李 辰,谭燕萍,毛振林,蒲妙强,范红星.灯盏花素注射液联合依达拉奉注射液对未溶栓急性脑梗死患者神经功能、脑血流动力学和血清炎症细胞因子的影响[J].,2022,(24):4691-4694 |
| 灯盏花素注射液联合依达拉奉注射液对未溶栓急性脑梗死患者神经功能、脑血流动力学和血清炎症细胞因子的影响 |
| Effects of Breviscapine Injection Combined with Edaravone Injection on Neurological Function, Cerebral Hemodynamics and Serum Inflammatory Cytokines in Patients with Non Thrombolytic Acute Cerebral Infarction |
| 投稿时间：2022-05-23 修订日期：2022-06-17 |
| DOI：10.13241/j.cnki.pmb.2022.24.017 |
| 中文关键词: 灯盏花素注射液 依达拉奉注射液 急性脑梗死 神经功能 脑血流动力学 炎症细胞因子 |
| 英文关键词: Breviscapine injection Edaravone injection Acute cerebral infarction Neurological function Cerebral hemodynamics Inflammatory cytokines |
| 基金项目:广东省基础与应用基础研究基金项目（2020A1515110009） |
|
| 摘要点击次数: 758 |
| 全文下载次数: 436 |
| 中文摘要: |
| 摘要 目的：观察灯盏花素注射液联合依达拉奉注射液对未溶栓急性脑梗死（ACI）患者神经功能、脑血流动力学和血清炎症细胞因子的影响。方法：选取2020年4月~2022年1月来我院接受治疗的未溶栓ACI患者82例。采用随机数字表法将患者分为对照组（依达拉奉注射液治疗，41例）和实验组（灯盏花素注射液联合依达拉奉注射液治疗，41例）。观察两组临床疗效，神经功能、脑血流动力学和血清炎症细胞因子的变化，记录两组不良反应情况。结果：实验组的临床总有效率为90.24%，高于对照组的68.29%，差异有统计学意义（P<0.05）。实验组治疗7d后美国国立卫生研究院卒中量表（NIHSS）评分低于对照组，日常生活活动能力（ADL）评分高于对照组P<0.05）。实验组治疗7d后脑血流平均血流速度（Vm）、收缩期峰值血流速度（Vs）、舒张期血流速度（Vd）高于对照组（P<0.05）。实验组治疗7 d后白介素-6（IL-6）、超敏C反应蛋白（hs-CRP）水平低于对照组（P<0.05）。两组均未出现严重的不良反应。结论：依达拉奉注射液联合灯盏花素注射液治疗未溶栓ACI患者，可调节脑血流动力学，减轻神经功能损伤，降低血清炎症细胞因子，且具有较好的安全性。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effects of Breviscapine injection combined with edaravone injection on neurological function, cerebral hemodynamics and serum inflammatory cytokines in patients with non thrombolytic acute cerebral infarction (ACI). Methods: 82 patients with non thrombolytic ACI who received treatment in our hospital from April 2020 to January 2022 were selected. The patients were randomly divided into control group (edaravone injection, 41 cases) and experimental group (Breviscapine injection combined with edaravone injection, 41 cases) by the random number table method. The clinical efficacy, neurological function, cerebral hemodynamics and serum inflammatory cytokines in the two groups were observed, and the adverse reactions in the two groups were recorded. Results: The total effective rate in the experimental group was 90.24%, which was higher than 68.29% in the control group, the difference was statistically significant(P<0.05). 7 d after treatment, the national Institutes of Health Stroke Scale (NIHSS) score of the experimental group was lower than that of the control group, and the activities of daily living (ADL)score of the experimental group was higher than that of the control group (P<0.05). 7 d after treatment, the average blood flow velocity (Vm), peak systolic blood flow velocity (Vs) and diastolic blood flow velocity (Vd) of cerebral blood flow in the experimental group were higher than those in the control group (P<0.05). 7 d after treatment, interleukin-6 (IL-6), high sensitivity C-reactive protein (hs-CRP) in the experimental group were lower than those of the control group (P<0.05). There were no serious adverse reactions in the two groups. Conclusion: Edaravone injection combined with Breviscapine injection in the treatment of patients with non thrombolytic ACI can regulate cerebral hemodynamics, reduce nerve function injury, reduce serum inflammatory cytokines, and which has a good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
